eClinical Solutions Market Size and Share Analysis by Type (Products, Professional Services), Delivery Mode (Web Based, Cloud Based, On-Premise), Clinical Trial Phase (Phase I, Phase II, Phase III, Phase IV), End User (Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, Healthcare Providers) - Global Industry Revenue Estimation and Demand Forecast to 2030

Market Overview

The global eClinical solutions market size stood at $7.18 billion in 2021, which is expected to reach $22.35 billion by 2030, advancing at a CAGR of 13.4% during 2021–2030. This is prominently attributed to the rising novel government policies and grants in the support of clinical trials. In addition, pharmaceutical and biotechnology companies’ rising need for R&D expenditure on drug development for the treatment of surging chronic diseases is another factor that is expected to propel the domain growth in the upcoming period.

The novel drug therapy industry and medical research are undergoing a paradigm shift away from traditional drug-based treatment to personalized disease management. When compared to existing alternative treatments or medications, government reimbursement organizations and private payers and insurers frequently demand improved efficacy and therapeutic value for novel drugs.

Furthermore, these payers control standard pricing for new medications, reducing profit margins for manufacturers. The eClinical industry is concentrating on the development and commercialization of software that can expedite and complete trial phases cost-effectively. The adoption of new business models by major biotechnology and pharmaceutical companies to reduce overall research costs is projected to drive the need for innovative and advanced eClinical software in the upcoming period.

Modern cloud computing helps companies to grasp new business opportunities and innovate faster. The healthcare industry is extensively implementing cloud-based technologies for exchanging medical, financial, and associated complex data by healthcare organizations. New plagiarism is emerging, which would shift the conduct and management of trials to a standardized suite of cloud-based applications.

Biopharmaceutical companies are using cloud-based technologies to efficiently reduce the time consumed and manage costs in the trial process. Moreover, these technologies are becoming an essential strategic decision for pharma IT players as a differentiator.

Increasing Clinical Research in Emerging Markets

Pharmaceutical companies are increasing the number of trials in developing countries, and thus, the frequency of clinical research is rising in these economies, due to low operational costs, availability of a large number of patients, faster recruitment rate, and the availability of CROs focused on global trials. In addition, fewer logistical problems and widespread adoption of guidelines, and stronger intellectual property protections are also driving the demand for clinical trials in emerging countries. This provides several opportunities for market players.

Web-Based Delivery Mode Being Used the Most

The web-based delivery mode held the largest eClinical solutions market share, of more than 70%, in 2021. This is because these solutions are readily customizable, due to which, healthcare providers can tailor the important medical data for various user groups. In addition, several benefits associated with this mode like easy to use, smooth accessibility, and lower investments are other factors burgeoning the market growth in this category. Furthermore, due to its higher level of interoperability, the category is expected to uphold its position in the upcoming period as well.

However, the demand for cloud-based delivery mode is expected to register the highest CAGR, of approximately 14.9%, in the forecast period, primarily attributed to several benefits such as integrated features like flexibility, low-handling costs, high accessibility, and simple data backup. This mode also provides real-time data, allowing users to make quick decisions and provide high-quality info for risk-based monitoring. These benefits are expected to increase the demand for cloud-based solutions.

Phase III Accounts for Highest Market Share

Among various clinical trial phases, phase III held the largest market share, of around 54%, in 2021. This is on account of the burgeoning need for the adoption of data management software in phase III trials for the reduction of costs and the improvement of trial efficiency. The rising number of drugs effectively reaching phase III trials is another factor augmenting the market growth in this category. Phase III comprises the study of the effectivity of a drug by employing a cluster of quite 1,000 patients. The complexity of the study will increase with a rise within the range of patients, which boosts the need for computer-based solutions for information management, thereby stimulating the incorporation of eClinical software.

However, the phase I category is set to register the highest CAGR, in the coming years. This can be ascribed to the excessive importance of eClinical solutions to predict future consequences of a drug candidate and cast-off drug molecules having the least probability of success. In addition, several innovations in personalized treatment technologies and biological modeling systems are stimulating the development of many novel drugs, thereby leading to a significant increase in the number of drug candidates undergoing the phase I trial.

Explore more about this report - Request free sample

eCOA Category To Register Highest CAGR

Amongst various products, the electronic clinical outcome assessment (eCOA) category is projected to record the highest CAGR, in the forecast period, owing to the increasing significance of superior quality data in the healthcare industry. The wide adoption of eCOA for the evaluation of clinician-reported, patient-reported, and observer-reported outcomes is driving the domain growth. In addition, eCOA enhances the quality of data captured, provides effective data analysis, and streamlines data collection procedures, which are driving its demand.

Furthermore, the rising need for patient compliance is increasing the use of these solutions to efficiently encounter challenges raised by paper-based medical records. The associated benefits of eCOA such as the reduction of site monitoring expenditures, the eradication of data variance risk, and streamlined data are other factors fueling the industry growth in this category. The need for the unification of research studies with patient care to form a patient-centric approach is also burgeoning the category size.

Clinical Research Organizations Dominate the Market Size

The CROs category accounted for the largest market size in 2021, on account of the surging utilization of eClinical solutions in pharmaceutical research, and benefits associated with the outsourcing of trials to CROs such as improved productivity, high service efficiency, and cost-effectiveness.

Pharmaceutical companies are shifting toward Eastern Europe and Asia for conducting cost-effective trials. Thus, the number of CROs is increasing in these regions, to conduct trials for various pharmaceutical companies. In countries such as Bulgaria, Hungary, China, and Poland, the number of research studies is rising, due to the speeding up of patient enrollment by CROs and reducing the cost of research activities. These CROs bring better opportunities for the growth of the sector.

However, the pharmaceutical and biotechnology companies category is set to record the highest CAGR, of more than 15%, during the upcoming period, owing to the rising adoption of eClinical solutions by researchers to enhance trials and streamline workflow. The major factor driving the demand for these solutions amongst pharmaceutical and biotechnology companies is the identification of procedural bottlenecks associated with clinical trials.

North America Is the Market Leader

North America led the eClinical solutions market in 2021, with a share of more than 50%. This is primarily ascribed to the surging prevalence of chronic and lifestyle-associated disorders like cardiovascular diseases and diabetes, the surging grants by government organizations, and the increasing launches of innovative products by vendors in the region. Furthermore, the presence of major players like OmniComm Systems Inc., ERT, BioClinica, PAREXEL International Corporation, and Medidata Solutions Inc. in the region is stimulating the market growth.

However, the APAC market is expected to record a noteworthy CAGR of more than 14% in the forecast period, due to the high demand for software coupled with the spur in the prevalence of chronic diseases like CVDs, cancer, and infectious diseases in the region. Moreover, the enormous patient population base and low costs of trials in nations like India, China, Japan, and Korea are receiving a rising number of drug trials from pharmaceutical companies. The adoption of eClinical services in these countries has also increased, as a result of outsourcing clinical trials. Additionally, the growing government funding for drug development and research is one of the main drivers of the APAC market's growth.

Top Players in the eClinical Solutions Market Are:

• Datatrak International Inc.
• Oracle Corporation
• Parexel International Corporation
• Dassault Systèmes S.A.
• Bioclinica Inc.
• Medidata Solutions Inc.
• DATATRAK International Inc.
• eClinicalWorks
• IBM Watson Health
• eClinical Solutions LLC

Market Size Breakdown by Segment

The report offers a comprehensive market segmentation analysis along with market estimation for the period 2017-2030.

Based on Type

• Products
  • Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS) 
  • Clinical Trial Management Systems (CTMS)
  • Clinical Analytics Platforms
  • Randomization and Trial Supply Management (RTSM) 
  • Clinical Data Integration Platforms
  • Electronic Clinical Outcome Assessment (eCOA)
  • Safety Solutions
  • Electronic Trial Master File (eTMF)
• Professional Services 

Based on Delivery Mode

• Web Based
• Cloud Based
• On-premise

Based on Clinical Trial Phase

• Phase I
• Phase II
• Phase III
• Phase IV

Based on End User

• Pharmaceutical and Biotechnology Companies
• Clinical Research Organizations (CROs)
• Healthcare Providers

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa